Jason Rhodes Sells 24,100 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 24,100 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $21.10, for a total transaction of $508,510.00. Following the sale, the director directly owned 1,081,044 shares in the company, valued at $22,810,028.40. This trade represents a 2.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

NASDAQ DYN opened at $20.61 on Friday. The company has a market cap of $3.41 billion, a price-to-earnings ratio of -6.40 and a beta of 1.09. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The stock’s fifty day moving average price is $18.43 and its 200 day moving average price is $18.09. Dyne Therapeutics, Inc. has a 1 year low of $8.06 and a 1 year high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period in the previous year, the company posted ($1.05) EPS. As a group, equities research analysts forecast that Dyne Therapeutics, Inc. will post -3 earnings per share for the current year.

Analyst Ratings Changes

DYN has been the topic of several analyst reports. Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th. TD Cowen started coverage on shares of Dyne Therapeutics in a research note on Friday. They set a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Morgan Stanley lowered their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Finally, Evercore set a $33.00 price objective on Dyne Therapeutics in a report on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and an average target price of $34.17.

Institutional Trading of Dyne Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of DYN. Hilton Head Capital Partners LLC acquired a new position in shares of Dyne Therapeutics during the 1st quarter worth about $26,000. Strs Ohio purchased a new stake in Dyne Therapeutics during the 4th quarter worth approximately $51,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Dyne Therapeutics during the fourth quarter valued at approximately $84,000. Steward Partners Investment Advisory LLC lifted its position in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after acquiring an additional 7,697 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.